Royalty Pharma (RPRX) Cash & Current Investments (2019 - 2026)

Royalty Pharma has disclosed Cash & Current Investments across 8 years of filings, most recently posting $837.0 million for Q2 2026.

• In Q2 2026, Cash & Current Investments rose 29.74% year-over-year to $837.0 million; the TTM figure through Jun 2026 stood at $837.0 million (up 29.74% YoY), while the FY2025 annual figure was $637.5 million, down 35.43% from the prior year.
• Cash & Current Investments came in at $837.0 million for Q2 2026 at Royalty Pharma, up from $608.3 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $2.5 billion in Q2 2022 to a low of $495.3 million in Q4 2023.
• Average Cash & Current Investments over 5 years is $1.3 billion, with a median of $992.9 million recorded in 2024.
• Year-over-year, Cash & Current Investments slumped 71.45% in 2023 and jumped 99.31% in 2024.
• Over 5 years, Cash & Current Investments stood at $1.7 billion in 2022, then sank by 71.45% to $495.3 million in 2023, then soared by 99.31% to $987.2 million in 2024, then plunged by 35.43% to $637.5 million in 2025, then surged by 31.29% to $837.0 million in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $837.0 million in Q2 2026, $608.3 million in Q1 2026, and $637.5 million in Q4 2025.